Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2016, Article ID 1654938, 8 pages
http://dx.doi.org/10.1155/2016/1654938
Review Article

The Need for Pediatric Formulations to Treat Children with HIV

1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2Academic Model Providing Access to Healthcare (AMPATH), Eldoret 30100, Kenya

Received 23 March 2016; Accepted 25 May 2016

Academic Editor: Charles Chiedza Maponga

Copyright © 2016 Adrienne F. Schlatter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART). ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research, provides a synopsis of the current data related to pediatric ART formulations and adherence.